

Product Data Sheet

Product Name: Icotrokinra hydrochloride

Cat. No.: GC79429

Chemical Properties

Cas. No.


Formula $C_{90}H_{120}N_{20}O_{22}S_2 \cdot xHCl$ M.Wt 1898.17

Solubility DMSO: 100 mg/mL (Need ultrasonic) Storage Sealed storage, away from moisture

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Icotrokinra (JNJ-77242113) hydrochloride is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra hydrochloride inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC_{50} =5.6 pM) and inhibits IL-23-induced interferon IFN- γ production in NK cells with an IC_{50} of 18.4 pM. Icotrokinra hydrochloride exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra hydrochloride can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease [1].

In Vivo, Icotrokinra (0.03-10 mg/kg; p.o.; once daily for 7 days) hydrochloride reduces the colon weight-to-length ratio and alleviates weight loss in rats with TNBS-induced colitis[1]. Icotrokinra (1-30 mg/kg; p.o.; twice daily for 3 days) hydrochloride prevents IL-23-induced upregulation of IL-17A and IL-22 in a rat skin inflammation model at doses greater than 10 mg/kg[1].

References:

[1]. Fourie AM, et al., JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep. 2024 Jul 30;14(1):17515.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA